Association of prolyl oligopeptidase with conventional neurotransmitters in the brain

CNS and Neurological Disorders - Drug Targets

Volumn 10, Issue 3, 2011, Pages 311-318

  Peltonen, Iida ^a   Myöhänen, Timo T ^a   Männistö, Pekka T ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Brain lesions; Immunohistochemistry; Neurotransmitters; PEP; POP; Prolyl endopeptidase; Prolyl oligopeptidase; Rat; Stereotaxis

Indexed keywords

4 AMINOBUTYRIC ACID; ACETYLCHOLINE; CATECHOLAMINE; DOPAMINE; GLUTAMIC ACID; NEUROTRANSMITTER; NORADRENALIN; PROLYL ENDOPEPTIDASE; SEROTONIN;

ARTICLE; BRAIN; CHOLINERGIC SYSTEM; HUMAN; NEUROTRANSMISSION; NONHUMAN;

EID: 79951694128     PISSN: 18715273     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152711794653887     Document Type: Article

References (71)

1. Rawlings, N.D.; Barrett, A.J. Families of serine peptidases. Methods Enzymol., 1994, 244, 19-61.
2. Polgar, L. Prolyl oligopeptidases. Methods Enzymol., 1994, 244, 188-200.
3. Cunningham, D.F.; O'Connor, B. A study of prolyl endopeptidase in bovine serum and its relevance to the tissue enzyme. Int. J. Biochem. Cell Biol., 1998, 30(1), 99-114.
4. García-Horsman, J.A.; Männistö, P.T.; Venäläinen, J.I. On the role of prolyl oligopeptidase in health and disease. Neuropeptides, 2007, 41(1), 1-24.
5. Männistö, P.T.; Venäläinen, J.; Jalkanen, A.; García-Horsman, J.A. Prolyl oligopeptidase: a potential target for the treatment of cognitive disorders. Drug News. Perspect., 2007, 20(5), 293-305.
6. Aoyagi, T.; Wada, T.; Nagai, M.; Kojima, F.; Harada, S.; Takeuchi, T.; Takahashi, H.; Hirokawa, K.; Tsumita, T. Deficiency of kallikrein-like enzyme activities in cerebral tissue of patients with Alzheimer's disease. Experientia, 1990, 46(1), 94-97.
7. Mantle, D.; Falkous, G.; Ishiura, S.; Blanchard, P.J.; Perry, E.K. Comparison of proline endopeptidase activity in brain tissue from normal cases and cases with Alzheimer's disease, Lewy body dementia, Parkinson's disease and Huntington's disease. Clin. Chim. Acta, 1996, 249(1-2), 129-139.
8. Agirregoitia, N.; Gil, J.; Ruiz, F.; Irazusta, J.; Casis, L. Effect of aging on rat tissue peptidase activities. J. Gerontol. A Biol. Sci. Med. Sci., 2003, 58(9), B792-B797.
9. Rossner, S.; Schulz, I.; Zeitschel, U.; Schliebs, R.; Bigl, V.; Demuth, H.U. Brain prolyl endopeptidase expression in aging, APP transgenic mice and Alzheimer's disease. Neurochem. Res., 2005, 30(6-7), 695-702.
10. Yoshimoto, T.; Kado, K.; Matsubara, F.; Koriyama, N.; Kaneto, H.; Tsura, D. Specific inhibitors for prolyl endopeptidase and their anti-amnesic effect. J. Pharmacobiodyn., 1987, 10(12), 730-735.
11. Toide, K.; Iwamoto, Y.; Fujiwara, T.; Abe, H. JTP-4819: a novel prolyl endopeptidase inhibitor with potential as a cognitive enhancer. J. Pharmacol. Exp. Ther., 1995, 274(3), 1370-1378.
12. Shinoda, M.; Matsuo, A.; Toide, K. Pharmacological studies of a novel prolyl endopeptidase inhibitor, JTP-4819, in rats with middle cerebral artery occlusion. Eur. J. Pharmacol., 1996, 305(1-3), 31-38.
13. Toide, K.; Shinoda, M.; Fujiwara, T.; Iwamoto, Y. Effect of a novel prolyl endopeptidase inhibitor, JTP-4819, on spatial memory and central cholinergic neurons in aged rats. Pharmacol. Biochem. Behav., 1997, 56(3), 427-434.
14. Morain, P.; Lestage, P.; De Nanteuil, G.; Jochemsen, R.; Robin, J.L.; Guez, D.; Boyer, P.A. S 17092: a prolyl endopeptidase inhibitor as a potential therapeutic drug for memory impairment. Preclinical and clinical studies. CNS Drug Rev., 2002, 8(1), 31-52.
15. Jalkanen, A.J.; Puttonen, K.A.; Venäläinen, J.I.; Sinervä, V.; Mannila, A.; Ruotsalainen, S.; Jarho, E.M.; Wallén, E.A.; Männistö, P.T. Beneficial effect of prolyl oligopeptidase inhibition on spatial memory in young but not in old scopolamine-treated rats. Basic Clin. Pharmacol. Toxicol., 2007, 100(2), 132-138.
16. Peltonen, I.; Jalkanen, A.J.; Sinervä, V.; Puttonen, K.A.; Männistö, P.T. Different effects of scopolamine and inhibition of prolyl oligopeptidase on mnemonic and motility functions of young and 8- to 9-month-old rats in the radial-arm maze. Basic Clin. Pharmacol. Toxicol., 2010, 106(4), 280-287.
17. Toide, K.; Okamiya, K.; Iwamoto, Y.; Kato, T. Effect of a novel prolyl endopeptidase inhibitor, JTP-4819, on prolyl endopeptidase activity and substance P- and arginine-vasopressin-like immunoreactivity in the brains of aged rats. J. Neurochem., 1995, 65(1), 234-240.
18. Toide, K.; Fujiwara, T.; Iwamoto, Y.; Shinoda, M.; Okamiya, K.; Kato, T. Effect of a novel prolyl endopeptidase inhibitor, JTP-4819, on neuropeptide metabolism in the rat brain. Naunyn Schmiedebergs Arch. Pharmacol., 1996, 353(3), 355-362.
19. Bellemere, G.; Morain, P.; Vaudry, H.; Jegou, S. Effect of S 17092, a novel prolyl endopeptidase inhibitor, on substance P and alphamelanocyte-stimulating hormone breakdown in the rat brain. J. Neurochem., 2003, 84(5), 919-929.
20. Bellemere, G.; Vaudry, H.; Morain, P.; Jegou, S. Effect of prolyl endopeptidase inhibition on arginine-vasopressin and thyrotrophinreleasing hormone catabolism in the rat brain. J. Neuroendocrinol., 2005, 17(5), 306-313.
21. Venäläinen, J.I.; Juvonen, R.O.; Männistö, P.T. Evolutionary relationships of the prolyl oligopeptidase family enzymes. Eur. J. Biochem., 2004, 271(13), 2705-2715.
22. Myöhänen, T.T.; García-Horsman, J.A.; Tenorio-Laranga, J.; Männistö, P.T. Issues about the physiological functions of prolyl oligopeptidase based on its discordant spatial association with substrates and inconsistencies among mRNA, protein levels, and enzymatic activity. J. Histochem. Cytochem., 2009, 57(9), 831-848.
23. Goossens, F.; De Meester, I.; Vanhoof, G.; Scharpe, S. Distribution of prolyl oligopeptidase in human peripheral tissues and body fluids. Eur. J. Clin. Chem. Clin. Biochem., 1996, 34(1), 17-22.
24. Cunningham, D.F.; O'Connor, B. Identification and initial characterisation of a N-benzyloxycarbonyl-prolyl-prolinal (Z-Proprolinal)-insensitive 7-(N-benzyloxycarbonyl-glycyl-prolyl-amido)-4-methylcoumarin (Z-Gly-Pro-NH-Mec)-hydrolysing peptidase in bovine serum. Eur. J. Biochem., 1997, 244(3), 900-903.
25. Dresdner, K.; Barker, L.A.; Orlowski, M.; Wilk, S. Subcellular distribution of prolyl endopeptidase and cation-sensitive neutral endopeptidase in rabbit brain. J. Neurochem., 1982, 38(4), 1151-1154.
26. O'Leary, R.M.; O'Connor, B. Identification and localisation of a synaptosomal membrane prolyl endopeptidase from bovine brain. Eur. J. Biochem., 1995, 227(1-2), 277-283.
27. Tenorio-Laranga, J.; Venäläinen, J.I.; Männistö, P.T.; García-Horsman, J.A. Characterization of membrane-bound prolyl endopeptidase from brain. FEBS J., 2008, 275(17), 4415-4427.
28. Myöhänen, T.T.; Venäläinen, J.I.; García-Horsman, J.A.; Piltonen, M.; Männistö, P.T. Distribution of prolyl oligopeptidase in the mouse whole-body sections and peripheral tissues. Histochem. Cell Biol., 2008, 130(5), 993-1003.
29. Ishino, T.; Ohtsuki, S.; Homma, K.; Natori, S. cDNA cloning of mouse prolyl endopeptidase and its involvement in DNA synthesis by Swiss 3T3 cells. J. Biochem., 1998, 123(3), 540-545.
30. Moreno-Baylach, M.J.; Felipo, V.; Männistö, P.T.; García-Horsman, J.A. Expression and traffic of cellular prolyl oligopeptidase are regulated during cerebellar granule cell differentiation, maturation, and aging. Neuroscience, 2008, 156(3), 580-585.
31. Schulz, I.; Zeitschel, U.; Rudolph, T.; Ruiz-Carrillo, D.; Rahfeld, J.U.; Gerhartz, B.; Bigl, V.; Demuth, H.U.; Rossner, S. Subcellular localization suggests novel functions for prolyl endopeptidase in protein secretion. J. Neurochem., 2005, 94(4), 970-979.
32. Ohtsuki, S.; Homma, K.; Kurata, S.; Komano, H.; Natori, S. A prolyl endopeptidase of Sarcophaga peregrina (flesh fly): its purification and suggestion for its participation in the differentiation of the imaginal discs. J. Biochem., 1994, 115(3), 449-453.
33. Brandt, I.; De Vriendt, K.; Devreese, B.; Van Beeumen, J.; Van Dongen, W.; Augustyns, K.; De Meester, I.; Scharpe, S.; Lambeir, A.M. Search for substrates for prolyl oligopeptidase in porcine brain. Peptides, 2005, 26(12), 2536-2546.
34. Di Daniel, E.; Glover, C.P.; Grot, E.; Chan, M.K.; Sanderson, T.H.; White, J.H.; Ellis, C.L.; Gallagher, K.T.; Uney, J.; Thomas, J.; Maycox, P.R.; Mudge, A.W. Prolyl oligopeptidase binds to GAP-43 and functions without its peptidase activity. Mol. Cell. Neurosci., 2009, 41(3), 373-382.
35. Paxinos, G. The Rat Nervous System, 3rd ed.; Elsevier Academic Press; San Diego, 2004.
36. Myöhänen, T.T.; Venäläinen, J.I.; García-Horsman, J.A.; Piltonen, M.; Männistö, P.T. Cellular and subcellular distribution of rat brain prolyl oligopeptidase and its association with specific neuronal neurotransmitters. J. Comp. Neurol., 2008, 507(5), 1694-1708.
37. Calabresi, P.; Centonze, D.; Gubellini, P.; Pisani, A.; Bernardi, G. Acetylcholine-mediated modulation of striatal function. Trends Neurosci., 2000, 23(3), 120-126.
38. Katsube, N.; Sunaga, K.; Chuang, D.; Ishitani, R. ONO-1603, a potential antidementia drug, shows neuroprotective effects and increases m3-muscarinic receptor mRNA levels in differentiating rat cerebellar granule neurons. Neurosci. Lett., 1996, 214(2-3), 151-154.
39. Toide, K.; Shinoda, M.; Takase, M.; Iwata, K.; Yoshida, H. Effects of a novel thyrotropin-releasing hormone analogue, JTP-2942, on extracellular acetylcholine and choline levels in the rat frontal cortex and hippocampus. Eur. J. Pharmacol., 1993, 233(1), 21-28.
40. Van der Zee, E.A.; Luiten, P.G.; Disterhoft, J.F. Learning-induced alterations in hippocampal PKC-immunoreactivity: a review and hypothesis of its functional significance. Prog. Neuropsychopharmacol. Biol. Psychiatry, 1997, 21(3), 531-572.
41. Myöhänen, T.T.; Kääräainen, T.M.; Jalkanen, A.J.; Piltonen, M.; Männistö, P.T. Localization of prolyl oligopeptidase in the thalamic and cortical projection neurons: a retrograde neurotracing study in the rat brain. Neurosci. Lett., 2009, 450(2), 201-205.
42. Arif, M.; Chikuma, T.; Ahmed, M.M.; Yoshida, S.; Kato, T. Suppressive effect of clozapine but not haloperidol on the increases of neuropeptide-degrading enzymes and glial cells in MK-801-treated rat brain regions. Neurosci. Res., 2007, 57(2), 248-258.
43. Kasparov, S.; Pawelzik, H.; Zieglgansberger, W. Thyrotropinreleasing hormone enhances excitatory postsynaptic potentials in neocortical neurons of the rat in vitro. Brain Res., 1994, 656(2), 229-235.
44. Williams, R.S.; Harwood, A.J. Lithium therapy and signal transduction. Trends Pharmacol. Sci., 2000, 21(2), 61-64.
45. Williams, R.S.; Cheng, L.; Mudge, A.W.; Harwood, A.J. A common mechanism of action for three mood-stabilizing drugs. Nature, 2002, 417(6886), 292-295.
46. Schulz, I.; Gerhartz, B.; Neubauer, A.; Holloschi, A.; Heiser, U.; Hafner, M.; Demuth, H.U. Modulation of inositol 1,4,5-triphosphate concentration by prolyl endopeptidase inhibition. Eur. J. Biochem., 2002, 269(23), 5813-5820.
47. Cheng, L.; Lumb, M.; Polgar, L.; Mudge, A.W. How can the mood stabilizer VPA limit both mania and depression? Mol. Cell. Neurosci., 2005, 29(2), 155-161.
48. Myöhänen, T.T.; Venäläinen, J.I.; García-Horsman, J.A.; Männistö, P.T. Spatial association of prolyl oligopeptidase, inositol 1,4,5-triphosphate type 1 receptor, substance P and its neurokinin-1 receptor in the rat brain: an immunohistochemical colocalization study. Neuroscience, 2008, 153(4), 1177-1189.
49. Lynch, M.A.; Voss, K.L. Presynaptic changes in long-term potentiation: elevated synaptosomal calcium concentration and basal phosphoinositide turnover in dentate gyrus. J. Neurochem., 1991, 56(1), 113-118.
50. Bliss, T.V.; Collingridge, G.L. A synaptic model of memory: longterm potentiation in the hippocampus. Nature, 1993, 361(6407), 31-39.
51. Khodakhah, K.; Armstrong, C.M. Induction of long-term depression and rebound potentiation by inositol trisphosphate in cerebellar Purkinje neurons. Proc. Natl. Acad. Sci. USA, 1997, 94(25), 14009-14014.
52. Jun, K.; Choi, G.; Yang, S.G.; Choi, K.Y.; Kim, H.; Chan, G.C.; Storm, D.R.; Albert, C.; Mayr, G.W.; Lee, C.J.; Shin, H.S. Enhanced hippocampal CA1 LTP but normal spatial learning in inositol 1,4,5-trisphosphate 3-kinase(A)-deficient mice. Learn. Mem., 1998, 5(4-5), 317-330.
53. Fujii, S.; Sasaki, H.; Mikoshiba, K.; Kuroda, Y.; Yamazaki, Y.; Mostafa Taufiq, A.; Kato, H. A chemical LTP induced by coactivation of metabotropic and N-methyl-D-aspartate glutamate receptors in hippocampal CA1 neurons. Brain Res., 2004, 999(1), 20-28.
54. Taufiq, A.M.; Fujii, S.; Yamazaki, Y.; Sasaki, H.; Kaneko, K.; Li, J.; Kato, H.; Mikoshiba, K. Involvement of IP3 receptors in LTP and LTD induction in guinea pig hippocampal CA1 neurons. Learn. Mem., 2005, 12(6), 594-600.
55. Berridge, M.J. Inositol trisphosphate and calcium signalling. Nature, 1993, 361(6410), 315-325.
56. de la Vega, M.T.; Nunez, A.; Montano, J.A. Carbachol stimulates inositol phosphate formation in rat thalamus slices through muscarinic M3-receptor activation. Neurosci. Lett., 1996, 213(1), 29-32.
57. Contreras, D. The role of T-channels in the generation of thalamocortical rhythms. CNS Neurol. Disord. Drug Targets, 2006, 5(6), 571-585.
58. Besson, M.J.; Graybiel, A.M.; Quinn, B. Co-expression of neuropeptides in the cat's striatum: an immunohistochemical study of substance P, dynorphin B and enkephalin. Neuroscience, 1990, 39(1), 33-58.
59. McGinty, J.F. Co-localization of GABA with other neuroactive substances in the basal ganglia. Prog. Brain Res., 2007, 160, 273-284.
60. Standaert, D.G.; Young, A.B. In: Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11th ed.; McGraw-Hill Medical Publishing Division: New York, 2006, pp. 527-545.
61. Skidgel, R.A.; Erdös, E.G. In: Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11th ed.; McGraw-Hill Medical Publishing Division: New York, 2006, pp. 629-651.
62. Inagaki, S.; Sakanaka, M.; Shiosaka, S.; Senba, E.; Takagi, H.; Takatsuki, K.; Kawai, Y.; Matsuzaki, T.; Iida, H.; Hara, Y.; Tohyama, M. Experimental and immunohistochemical studies on the cerebellar substance P of the rat: localization, postnatal ontogeny and ways of entry to the cerebellum. Neuroscience, 1982, 7(3), 639-645.
63. Del Fiacco, M.; Perra, M.T.; Quartu, M.; Rosa, M.D.; Zucca, G.; Levanti, M.C. Evidence for the presence of substance P-like immunoreactivity in the human cerebellum. Brain Res., 1988, 446(1), 173-177.
64. Nakaya, Y.; Kaneko, T.; Shigemoto, R.; Nakanishi, S.; Mizuno, N. Immunohistochemical localization of substance P receptor in the central nervous system of the adult rat. J. Comp. Neurol., 1994, 347(2), 249-274.
65. Emson, P.C.; Lindvall, O. Distribution of putative neurotransmitters in the neocortex. Neuroscience, 1979, 4(1), 1-30.
66. Kawaguchi, Y.; Kondo, S. Parvalbumin, somatostatin and cholecystokinin as chemical markers for specific GABAergic interneuron types in the rat frontal cortex. J. Neurocytol., 2002, 31(3-5), 277-287.
67. Krupina, N.A.; Zolotov, N.N.; Bogdanova, N.G.; Orlova, I.N.; Khlebnikova, N.N.; Kryzhanovskii, G.N. Activities of prolyl endopeptidase and dipeptidyl peptidase IV in brain structures of rats with dopamine deficiency-dependent MPTP-induced depressive syndrome. Bull. Exp. Biol. Med., 2006, 142(5), 554-556.
68. Re, R.N.; Cook, J.L. The intracrine hypothesis: an update. Regul. Pept., 2006, 133(1-3), 1-9.
69. Shen, J.X.; Yakel, J.L. Nicotinic acetylcholine receptor-mediated calcium signalling in the nervous system. Acta Pharmacol. Sin., 2009, 30(6), 673-680.
70. Wei, J.; Zhang, M.; Zhu, Y.; Wang, J.H. Ca(2+)-calmodulin signalling pathway up-regulates GABA synaptic transmission through cytoskeleton-mediated mechanisms. Neuroscience, 2004, 127(3), 637-647.
71. Conn, P.J.; Sanders-Bush, E.; Hoffman, B.J.; Hartig, P.R. A unique serotonin receptor in choroid plexus is linked to phosphatidylinositol turnover. Proc. Natl. Acad. Sci. USA, 1986, 83(11), 4086-4088.